Literature DB >> 11689383

Therapeutic uses of vitamin D analogues.

A J Brown1.   

Abstract

The vitamin D endocrine system has been implicated in numerous biological activities throughout the body. The breadth and magnitude of vitamin D activity suggest potential therapeutic applications for the treatment of several diseases and disorders, including hyperproliferative diseases, immune dysfunction, endocrine disorders, and metabolic bone diseases. However, therapy using natural vitamin D hormone, 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) has been precluded in most cases because of the potent calcemic activity shown by this hormone. Newly developed vitamin D analogues with lower calcemic activity have been shown to retain many therapeutic properties of 1,25(OH)(2)D(3). Molecular studies discussed in this article provide insights into the unique target cell specificity afforded by these analogues. In particular, the importance of the nuclear vitamin D receptor (VDR), serum vitamin D-binding protein, 24-hydroxylase, and membrane receptor is noted because analogue selectivity, specificity, and potency are afforded through their molecular interactions. The nuclear VDR has been isolated from a variety of target cells and tissues, suggesting that vitamin D compounds may have therapeutic potential throughout several body systems. Five vitamin D analogues have been approved for use in patients: calcipotriol (Dovonex; Leo Pharmaceuticals, Copenhagen, Denmark) for the treatment of psoriasis, 19-nor-1,25(OH)(2)D(2) (Zemplar; Abbott Laboratories, Abbott Park, IL) for secondary hyperparathyroidism, doxercalciferol (Hectorol; Bone Care Int, Madison, WI) for reduction of elevated parathyroid hormone levels, 22-oxacalcitriol (Maxacalcitol; Chugai Pharmaceuticals, Tokyo, Japan), and alfacalcidol. Several other analogues are currently being tested in preclinical and clinical trials for the treatment of various types of cancer and osteoporosis, as well as immunosuppression. Understanding how analogues exert their selective actions may allow for the design of more effective and safer vitamin D compounds for the treatment of a wide range of clinical disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689383     DOI: 10.1053/ajkd.2001.28111

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

1.  Bias in research and conflict of interest: why should we care?

Authors:  H P Dietz
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-11-21

Review 2.  Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward.

Authors:  Myles Wolf; Ravi Thadhani
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-02       Impact factor: 4.292

Review 3.  Hormone replacement after thyroid and parathyroid surgery.

Authors:  Andreas Schäffler
Journal:  Dtsch Arztebl Int       Date:  2010-11-26       Impact factor: 5.594

Review 4.  A novel vitamin D-regulated immediate-early gene, IEX-1, alters cellular growth and apoptosis.

Authors:  Rajiv Kumar; Mark R Pittelkow; Jeffrey L Salisbury; Joseph P Grande; Hee-Jeong Im; Kathrin A Feldmann; David Schilling
Journal:  Recent Results Cancer Res       Date:  2003

5.  Vitamin D-binding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo.

Authors:  Lee A Zella; Nirupama K Shevde; Bruce W Hollis; Nancy E Cooke; J Wesley Pike
Journal:  Endocrinology       Date:  2008-03-27       Impact factor: 4.736

6.  1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.

Authors:  Paul R van Ginkel; William Yang; Marcus M Marcet; Clement C Chow; Amol D Kulkarni; Soesiawati Darjatmoko; Mary J Lindstrom; Janice Lokken; Saswati Bhattacharya; Daniel M Albert
Journal:  J Neurooncol       Date:  2007-06-30       Impact factor: 4.130

Review 7.  Protective cardiovascular and renal actions of vitamin D and estrogen.

Authors:  Pandu R Gangula; Yuan-Lin Dong; Ayman Al-Hendy; Gloria Richard-Davis; Valerie Montgomery-Rice; Georges Haddad; Rihcard Millis; Susanne B Nicholas; Diane Moseberry
Journal:  Front Biosci (Schol Ed)       Date:  2013-01-01

8.  Influence of the season on vitamin D levels and regulatory T cells in patients with polymorphic light eruption.

Authors:  N A Schweintzger; A Gruber-Wackernagel; N Shirsath; F Quehenberger; B Obermayer-Pietsch; P Wolf
Journal:  Photochem Photobiol Sci       Date:  2016-02-25       Impact factor: 3.982

9.  Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation.

Authors:  Marcus O W Grimm; Andrea Thiel; Anna A Lauer; Jakob Winkler; Johannes Lehmann; Liesa Regner; Christopher Nelke; Daniel Janitschke; Céline Benoist; Olga Streidenberger; Hannah Stötzel; Kristina Endres; Christian Herr; Christoph Beisswenger; Heike S Grimm; Robert Bals; Frank Lammert; Tobias Hartmann
Journal:  Int J Mol Sci       Date:  2017-12-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.